Home > Archive>Volume 13, Issue 9, 2020 >1477-1483. DOI:10.18240/ijo.2020.09.21
HTML XML Export Cite reminder
Increased vitreal levels of interleukin-10 in diabetic retinopathy: a Meta-analysis
Author:
Corresponding Author:

Ye-Di Zhou. Department of Ophthalmology, the Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, China. zhouyedi@csu.edu.cn

Fund Project:

Supported by National Natural Science Foundation of China (No.81800855; No.81770930); Natural Science Foundation of Hunan Province (No.2018JJ3765); Changsha Science and Technology Project (No.kq1907075); Department of Science and Technology, Hunan (No.2015TP2007).

  • Article
    • | |
  • Metrics
    • |
  • Reference [41]
    • |
  • Related
    • |
  • Cited by
    • | |
  • Comments
    Abstract:

    AIM: To conduct a Meta-analysis for the change of interleukin-10 (IL-10) concentration in vitreous samples of patients with diabetic retinopathy (DR). METHODS: Systemic search for literature was conducted from the databases of PubMed, Web of Science and Cochrane Library by August 2019. Statistical analyses including standard mean difference (SMD) and its 95% confidence interval (CI) were performed by using RevMan 5.3 software. RESULTS: Totally 194 studies were screened and finally 11 studies were included in the Meta-analysis. The concentration of IL-10 in the DR group was higher than in the control group (P=0.003, SMD: 0.77, 95%CI: 0.25-1.28). Significant heterogeneity was found among all studies (P<0.00001, I2=92%). The subgroup analysis showed that the concentration of IL-10 increased in vitreous samples from patients with DR compared to the non-DR controls (P=0.004, SMD: 1.44, 95%CI: 0.46-2.42). Moreover, the concentration of IL-10 in samples of proliferative diabetic retinopathy (PDR) patients was significantly higher than that of non-proliferative diabetic retinopathy (NPDR) patients (P=0.01, SMD: 0.61, 95%CI: 0.13-1.08). CONCLUSION: The vitreal concentration of IL-10 is significantly increased in patients with DR. Further studies are needed to reveal the mechanisms of IL-10 in DR.

    Reference
    1 Hua CH, Huynh-The T, Kim K, Yu SY, Le-Tien T, Park GH, Bang J, Khan WA, Bae SH, Lee S. Bimodal learning via trilogy of skip-connection deep networks for diabetic retinopathy risk progression identification. Int J Med Inform 2019;132:103926.
    2 May M, Framke T, Junker B, Framme C, Pielen A, Schindler C. How and why SGLT2 inhibitors should be explored as potential treatment option in diabetic retinopathy: clinical concept and methodology. Ther Adv Endocrinol Metab 2019;10:2042018819891886.
    3 Sadat Mahmoudi Nezhad G, Razeghinejad R, Janghorbani M, Mohamadian A, Hassan Jalalpour M, Bazdar S, Salehi A, Molavi Vardanjani H. Prevalence, incidence and ecological determinants of diabetic retinopathy in Iran: systematic review and meta-analysis. J Ophthalmic Vis Res 2019;14(3):321-335.
    4 Genz J, Scheer M, Trautner C, Zöllner I, Giani G, Icks A. Reduced incidence of blindness in relation to diabetes mellitus in southern Germany? Diabet Med 2010;27(10):1138-1143.
    5 Hu YG, Xie AM, Cheng QC. Upregulated CD200 in pre-retinal proliferative fibrovascular membranes of proliferative diabetic retinopathy patients and its correlation with vascular endothelial growth factor. Inflamm Res 2019;68(12):1071-1079.
    6 Ishibazawa A, De Pretto LR, Alibhai AY, Moult EM, Arya M, Sorour O, Mehta N, Baumal CR, Witkin AJ, Yoshida A, Duker JS, Fujimoto JG, Waheed NK. Retinal nonperfusion relationship to arteries or veins observed on widefield optical coherence tomography angiography in diabetic retinopathy. Invest Ophthalmol Vis Sci 2019;60(13):4310-4318.
    7 Ang WJ, Zunaina E, Norfadzillah AJ, Raja-Norliza RO, Julieana M, Ab-Hamid SA, Mahaneem M. Evaluation of vascular endothelial growth factor levels in tears and serum among diabetic patients. PLoS One 2019;14(8):e0221481.
    8 Tsubota K, Usui Y, Wakabayashi Y, Suzuki J, Ueda S, Goto H. Effectiveness of prophylactic intravitreal bevacizumab injection to proliferative diabetic retinopathy patients with elevated preoperative intraocular VEGF in preventing complications after vitrectomy. Clin Ophthalmol 2019;13:1063-1070.
    9 Zhou ZW, Ju HX, Sun MZ, Chen HM. Serum vascular endothelial growth factor levels correlate with severity of retinopathy in diabetic patients: a systematic review and meta-analysis. Dis Markers 2019;2019:9401628.
    10 Bressler NM, Beaulieu WT, Bressler SB, Glassman AR, Melia BM, Jampol LM, Jhaveri CD, Salehi-Had H, Velez G, Sun JK, DRCR Retina Network. Anti-vascular endothelial growth factor therapy and risk of traction retinal detachment in eyes with proliferative diabetic retinopathy: pooled analysis of five drcr retina network randomized clinical trials. Retina 2020;40(6):1021-1028.
    11 Spencer BG, Estevez JJ, Liu E, Craig JE, Finnie JW. Pericytes, inflammation, and diabetic retinopathy. Inflammopharmacology 2020;28(3):697-709.
    12 Youngblood H, Robinson R, Sharma A, Sharma S. Proteomic biomarkers of retinal inflammation in diabetic retinopathy. Int J Mol Sci 2019;20(19):E4755.
    13 Yao Y, Li R, Du JH, Long LH, Li XN, Luo N. Interleukin-6 and diabetic retinopathy: a systematic review and meta-analysis. Curr Eye Res 2019;44(5):564-574.
    14 Sabat R, Grutz G, Warszawska K, Kirsch S, Witte E, Wolk K, Geginat J. Biology of interleukin-10. Cytokine Growth Factor Rev 2010;21(5):331-344.
    15 Dace DS, Khan AA, Kelly J, Apte RS. Interleukin-10 promotes pathological angiogenesis by regulating macrophage response to hypoxia during development. PLoS One 2008;3(10):e3381.
    16 Nakamura R, Sene A, Santeford A, Gdoura A, Kubota S, Zapata N, Apte RS. IL10-driven STAT3 signalling in senescent macrophages promotes pathological eye angiogenesis. Nat Commun 2015;6:7847.
    17 Apte RS, Richter J, Herndon J, Ferguson TA. Macrophages inhibit neovascularization in a murine model of age-related macular degeneration. PLoS Med 2006;3(8):e310.
    18 Wu WK, Llewellyn OP, Bates DO, Nicholson LB, Dick AD. IL-10 regulation of macrophage VEGF production is dependent on macrophage polarisation and hypoxia. Immunobiology 2010;215(9-10):796-803.
    19 Zhao Q, Ji ML, Wang XM. IL-10 inhibits retinal pigment epithelium cell proliferation and migration through regulation of VEGF in rhegmatogenous retinal detachment. Mol Med Rep 2018;17(5):7301-7306.
    20 Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25(9):603-605.
    21 Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62(10):1006-1012.
    22 Chernykh VV, Varvarinsky EV, Smirnov EV, Chernykh DV, Trunov AN. Proliferative and inflammatory factors in the vitreous of patients with proliferative diabetic retinopathy. Indian J Ophthalmol 2015;63(1):33-36.
    23 Koskela UE, Kuusisto SM, Nissinen AE, Savolainen MJ, Liinamaa MJ. High vitreous concentration of IL-6 and IL-8, but not of adhesion molecules in relation to plasma concentrations in proliferative diabetic retinopathy. Ophthalmic Res 2013;49(2):108-114.
    24 Suzuki Y, Nakazawa M, Suzuki K, Yamazaki H, Miyagawa Y. Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion. Jpn J Ophthalmol 2011;55(3):256-263.
    25 Takeuchi M, Sato T, Tanaka A, Muraoka T, Taguchi M, Sakurai Y, Karasawa Y, Ito M. Elevated levels of cytokines associated with Th2 and Th17 cells in vitreous fluid of proliferative diabetic retinopathy patients. PLoS One 2015;10(9):e0137358.
    26 Xu Y, Cheng QC, Yang BY, Yu SS, Xu F, Lu L, Liang XL. Increased sCD200 levels in vitreous of patients with proliferative diabetic retinopathy and its correlation with VEGF and proinflammatory cytokines. Invest Ophthalmol Vis Sci 2015;56(11):6565-6572.
    27 Yabanoglu DA, Tan CS, Kadayifcilar S, Eldem B, Karahan S. Effect of adipose tissue-derived inflammatory and proangiogenic cytokines on proliferative diabetic retinopathy. Turk J Biochem 2014;39(4):495-502.
    28 Bromberg-White JL, Glazer L, Downer R, Furge K, Boguslawski E, Duesbery NS. Identification of VEGF-independent cytokines in proliferative diabetic retinopathy vitreous. Invest Ophthalmol Vis Sci 2013;54(10):6472-6480.
    29 Lee JH, Lee W, Kwon OH, Kim JH, Kwon OW, Kim KH, Lim JB. Cytokine profile of peripheral blood in type 2 diabetes mellitus patients with diabetic retinopathy. Ann Clin Lab Sci 2008;38(4):361-367.
    30 Wu HL, Hwang DK, Song XD, Tao Y. Association between aqueous cytokines and diabetic retinopathy stage. J Ophthalmol 2017;2017:9402198.
    31 Kaviarasan K, Jithu M, Arif Mulla M, Sharma T, Sivasankar S, Das UN, Angayarkanni N. Low blood and vitreal BDNF, LXA4 and altered Th1/Th2 cytokine balance are potential risk factors for diabetic retinopathy. Metab Clin Exp 2015;64(9):958-966.
    32 Ozturk BT, Bozkurt B, Kerimoglu H, Okka M, Kamis U, Gunduz K. Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness. Mol Vis 2009;15:1906-1914.
    33 Gupta P, Gan ATL, Man REK, Fenwick EK, Sabanayagam C, Mitchell P, Cheung CY, Cheung N, Wong TY, Cheng CY, Lamoureux EL. Association between diabetic retinopathy and incident cognitive impairment. Br J Ophthalmol 2019;103(11):1605-1609.
    34 Ting DS, Cheung GC, Wong TY. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clin Exp Ophthalmol 2016;44(4):260-277.
    35 Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010;376(9735):124-136.
    36 Yau JWY, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35(3):556-564.
    37 Ben ÂJ, Neyeloff JL, de Souza CF, Rosses APO, de Araujo AL, Szortika A, Locatelli F, de Carvalho G, Neumann CR. Cost-utility analysis of opportunistic and systematic diabetic retinopathy screening strategies from the perspective of the Brazilian public healthcare system. Appl Health Econ Health Policy 2020;18(1):57-68.
    38 Wang C, You QS, Cao XS, Guo HL, Gao XX, Peng XY. Micro RNA-19a suppresses interleukin-10 in peripheral B cells of patients with diabetic retinopathy. Am J Transl Res 2017;9(3):1410-1417.
    39 Cheung CM, Vania M, Ang M, Chee SP, Li J. Comparison of aqueous humor cytokine and chemokine levels in diabetic patients with and without retinopathy. Mol Vis 2012;18:830-837.
    40 Mao CJ, Yan H. Roles of elevated intravitreal IL-1β and IL-10 levels in proliferative diabetic retinopathy. Indian J Ophthalmol 2014;62(6): 699-701.
    41 My?liwiec M, Zorena K, Balcerska A, My?liwska J, Lipowski P, Raczyńska K. The activity of N-acetyl-beta-D-glucosaminidase and tumor necrosis factor-alpha at early stage of diabetic retinopathy development in type 1 diabetes mellitus children. Clin Biochem 2006;39(8):851-856.
    Related
    Cited by
Get Citation

Wei Tan, Jing-Ling Zou, Shigeo Yoshida,/et al.Increased vitreal levels of interleukin-10 in diabetic retinopathy: a Meta-analysis. Int J Ophthalmol, 2020,13(9):1477-1483

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
Publication History
  • Received:April 13,2020
  • Revised:May 27,2020
  • Online: July 21,2020
You are the  Visitors
Governing Body：Department of Health, Provincial Government of Shaanxi, China
Organizer：Xi'an Medical Association of China
Address：Room 11707-08, Building 2, Unit 1, Wanda Plaza, No.8 Yanta North Road, Xi'an 710054, Shaanxi Province, China
Fax：(8629)82245172 Phone：(+8629)82245172/82210956
Email：ijopress@163.com
International Journal of Ophthalmology ® 2025 All Rights Reserved   The terms of CC BY-NC-ND 4.0 are applicable to all open access content.